Influenza News and Research

Latest Influenza News and Research

First Edition: October 16, 2013

Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate.

16 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Measles-containing vaccines administered at 12-5 months of age associated with reduced risk of fever, seizures

Children receiving measles-containing vaccines at 12-15 months of age have a lower increased risk of fever and seizures than those who receive them at 16-23 months of age, according to a new Kaiser Permanente study published in JAMA Pediatrics.

15 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Gov't shutdown triggered by Capitol Hill causes damage to public health

The Centers for Disease Control and Prevention calls in furloughed scientists after a salmonella outbreak in California sickened people in 18 states.

10 Oct 2013

Lakewood-Amedex, Wainwright enter into strategic advisory agreement

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

The Knut and Alice Wallenberg Foundation will give a little over SEK 16 million to the development of new, highly-efficient mucosal vaccines. The vaccines will be drinkable or given as a nasal spray. Professor Nils Lycke at MIVAC at the Sahlgrenska Academy will in cooperation with researchers at Chalmers University of Technology and Lund University, combine technologies to develop the next generation of effective mucosal vaccines based on immunomodulation and cell-targeted nanoparticles.

9 Oct 2013

FMCNA encourages dialysis patients to get vaccinated against flu

With early cases of seasonal flu already being reported in the U.S., Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is strongly encouraging dialysis patients to get flu shots to protect themselves against this common infectious disease.

9 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Genetically modified bacterial treatment approach reduces or eliminates sleeping sickness

A tag team of two bacteria, one of them genetically modified, has a good chance to reduce or even eliminate the deadly disease African trypanosomiasis, or sleeping sickness, researchers at Oregon State University conclude in a recent mathematical modeling study.

4 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

No health law budging from either side as gov't shutdown continues

Neither Republicans nor Democrats appear ready to budge in the short-term to end a government shutdown and their impasse over funding for the health law. House Republicans are looking to pressure moderate Democrats in the Senate by sending the upper chamber a series of bills aimed at getting them to split from Senate Majority Leader Harry Reid, but Republicans are beginning to feel the pressure building themselves over who will get the blame for the shutdown.

3 Oct 2013

UCLA study shows how cocaine makes immune cells susceptible to HIV

In many ways, the spread of HIV has been fueled by substance abuse. Shared needles and drug users' high-risk sexual behaviors are just some of the ways that narcotics such as cocaine have played a key role in the AIDS epidemic in much of the world.

3 Oct 2013

New research shows no increased danger for egg allergic children who take flu shots

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, published in the October issue of the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology.

2 Oct 2013

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Canada should begin screening 'Baby Boomers' for the hepatitis C virus infection, since this age group is likely the largest group to have the illness, and most don't know they have it, say a group of liver specialists in the Toronto Western Hospital Francis Family Liver Clinic. Unlike many other chronic viral infections, early treatment makes hepatitis C curable.

1 Oct 2013

Virginia Tech faculty receives NIH New Innovator Award to research on influenza transmission

Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Patients treated by ID physicians less likely to die in hospital

In a first-of-its-kind study to evaluate the impact of a medical specialty on patient outcomes, researchers found that hospitalized patients with severe infections such as meningitis and Clostridium difficile are significantly less likely to die if they receive care from an infectious diseases specialist. The study, which analyzed nearly 130,000 Medicare patient cases, is now available online and will be published in the December 15 issue of Clinical Infectious Diseases.

30 Sep 2013

Influenza News and Research

Latest Influenza News and Research

First Edition: October 16, 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Measles-containing vaccines administered at 12-5 months of age associated with reduced risk of fever, seizures

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

Gov't shutdown triggered by Capitol Hill causes damage to public health

Lakewood-Amedex, Wainwright enter into strategic advisory agreement

Healthcare providers report unaccompanied teens may not receive required vaccines

Researchers to develop effective mucosal vaccines based on cell-targeted nanoparticles

FMCNA encourages dialysis patients to get vaccinated against flu

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

Genetically modified bacterial treatment approach reduces or eliminates sleeping sickness

J&J's Janssen Companies Launch A Trio Of Collaborations

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

No health law budging from either side as gov't shutdown continues

UCLA study shows how cocaine makes immune cells susceptible to HIV

New research shows no increased danger for egg allergic children who take flu shots

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Virginia Tech faculty receives NIH New Innovator Award to research on influenza transmission

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Patients treated by ID physicians less likely to die in hospital

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Influenza News and Research

Latest Influenza News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in